ISIS 9069
Latest Information Update: 07 Apr 2003
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Phosphotransferase inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Vascular restenosis
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 07 Apr 2003 No development reported - Preclinical for Vascular restenosis in USA (unspecified route)
- 03 Mar 2000 Preclinical development for Vascular restenosis in USA (Unknown route)